PATIENTS

Are you experiencing inadequate seizure control with you current regimen of anti-seizure medications?

NeuroPro has modified an FDA approved class of drugs that have a proven track record of safety that spans half a century. The goal is to create a more effective anti-seizure medication with fewer side effects.

How to Participate

If you have been diagnosed with epilepsy and are currently being treated with prescription medications, you may be eligible for participation in a clinical trial for a new anti-epileptic drug.

If you would like to participate in the clinical study please speak with your healthcare provider about contacting NeuroPro. The Phase 2 clinical study is planned to begin in 2024. After the study completes, there will be an option for patients to continue taking the investigational product for up to one year. 

Frequently Asked Questions About Participating in a Clinical Trial for a New Antiepileptic Drug

The purpose of the trial is to study the safety and effectiveness of this investigational product that may provide patients with improved and safer seizure control.

Yes, you will be able to remain on your current epilepsy medications.

Your doctor will not know if the treatment is working until the clinical trial is completed. Progress will be monitored by a team of clinicians responsible for review of patient data. When the study is completed your doctor can be informed of your treatment results if you consent.

The researchers believed that this new treatment will target the underlying electrophysiologic cause of seizure activity. This targeted approach could result in better seizure control with less side effects.

Speak with your healthcare provider to learn more about NeuroPro's upcoming clinical trial